top of page

Our single objective: to prevent and reverse disability for everyone with multiple sclerosis, neuromyelitis optica and MOG associated disease.

Research Themes

We are achieving this objective through six themes:​

  1. Personalising Treatments through Big Data and AI

  2. Discovering and Proving New Repair therapies

  3. Our Visual and MRI Outcome Development Program

  4. Studying Children with MS, NMO and related conditions

  5. Study ageing in multiple sclerosis

  6. Measuring and sustainably addressing healthcare inequalities.

Currently our work is focused on:
 

  • Improving the availability of data in electonic health records in the UK for MS researchers

  • Using real-world data to answer important questions about how best to use MS therapies

  • Exploring how best to measure remyelination in adults and children with MS

  • Investigating natural remyelination in people with MS

  • Doing clinical trials to identify drugs which promote endogenous remyelination in people with MS

​​

Read more here.

Featured News

CCMR2 fully recruited!

23rd August 2024

 

It is with great pleasure that we announce that we have completed recruitment of our CCMR2 trial, which will assess the effectiveness of metformin and clemastine to repair myelin damage in people living with multiple sclerosis.

Learn more about this trial here.

 

Remyelination is achievable

22nd May 2024

 

A recent publication, led by Dr Chris McMurran, has found that the remyelination effects observed in CCMR1 were sustained beyond the initial trial period.  The paper concludes that "this supports the increasingly clear position that pharmacological promotion of remyelination in people living with multiple sclerosis is possible and indicates a sustainability to repair following treatment with a remyelinating drug".

Continue reading here.

 

Non-disabling relapses count too!

6th March 2023

 

Great work from Cyrus published in the Multiple Sclerosis Journal The prognostic significance of non-disabling relapses in people with relapsing-remitting multiple sclerosis (RRMS) is unclear.

​

Continue reading here.

Remyelination varies markedly within and between lesions

12th January 2023

​

In multiple sclerosis chronic demyelination is associated with axonal loss, and ultimately contributes to irreversible progressive disability. Enhancing remyelination may slow, or even reverse, disability.

​

Continue reading here.

​

FOR PEOPLE WITH MS

bottom of page